Alopecia classification

Revision as of 01:17, 3 January 2021 by Nnabude (talk | contribs)
Jump to navigation Jump to search


Alopecia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alopecia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Laser Therapy

Concealing Hair Loss

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alopecia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alopecia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alopecia classification

CDC on Alopecia classification

Alopecia classification in the news

Blogs on Alopecia classification

Directions to Hospitals Treating Alopecia

Risk calculators and risk factors for Alopecia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogechukwu Hannah Nnabude, MD

Overview

Alopecia can be subdivided into two main categories: non-scarring and scarring. Over all, non-scarring alopecia has a higher possibility of being reversible and having a better outcome while scarring alopecia is more likely to be irreversible and have a poorer outcome.

Classification

Alopecia may be classified according to the scarring into 2 subtypes/groups: non-scarring and scarring.
The six major categories of non-scarring alopecia are:

  • Alopecia areata: this can affect any part of the body. When it affects only a portion of an area of the body, it is called alopecia areata. When it affects the entire site, it is called alopecia totalis. When it involves the whole body, it is called alopecia Universalis. The etiology is unknown, but it might be related to an autoimmune disease.[1]
  • Anagen effluvium: This is hair shedding that occurs during the anagen phase of the cell cycle. Seen in cancer patients who are receiving chemotherapeutic agents.
  • Androgenetic alopecia: is a pattern of hair loss that is affected by the hormones and genes.
  • Telogen effluvium: results from shifting of hair growth cycle from the anagen phase towards the telogen phase. It may result from an illness like hypothyroidism or hyperthyroidism. Also, it can arise from stress like major surgery or severe psychological stress [2]. Other causes include drugs, crash diet, poor feeding. [3]
  • Tinea capitis: the classical kind of tinea capitis (black-dots) causes non-scarring hair loss, unlike other types like kerion and favus.
  • Traumatic alopecia: This results from forceful traction of the hair. It is commonly seen in children and is similar to traction alopecia. Also, trichotillomania is a type of traumatic alopecia in which the patient pulls on his/her hair repeatedly. [4]

Scarring alopecia is divided into three major types:

  • Alopecia mucinosa: This occurs when mucinous material accumulates in the hair follicles and the sebaceous glands. The mucinous material causes an inflammatory response that hinders the growth of hair.
  • Alopecia neoplastica: This occurs when there is metastatic infiltration of the scalp hair with malignant cells.
  • Tinea capitis: This is the inflammatory variety of tinea capitis (favus) or kerion, which is when the fungi cause abscess formation, which may culminate with scarring alopecia.

References

  1. Lee YB, Jun M, Lee WS (2019). "Alopecia areata and poliosis: A retrospective analysis of 258 cases". J Am Acad Dermatol. 80 (6): 1776–1778. doi:10.1016/j.jaad.2018.11.033. PMID 30502419.
  2. 2.0 2.1 Nalluri R, Harries M (2016) Alopecia in general medicine. Clin Med (Lond) 16 (1):74-8. DOI:10.7861/clinmedicine.16-1-74 PMID: 26833522
  3. Liu LY, King BA (2019) Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. J Am Acad Dermatol 80 (6):1778-1779. DOI:10.1016/j.jaad.2018.11.037 PMID: 30502414
  4. Chen P, Chen F, Zhou B (2019). "The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis". Cutan Ocul Toxicol. 38 (2): 105–111. doi:10.1080/15569527.2018.1553180. PMID 30501438.
  5. 5.0 5.1 Vary JC (2015) Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Med Clin North Am 99 (6):1195-211. DOI:10.1016/j.mcna.2015.07.003 PMID: 26476248